Measurement Comparability of Insulin Assays Using Conventional Immunoassay Kits
1. Introduction
Immunoassays are essential analytical techniques widely used for the detection and quantification of biomolecules, particularly proteins and peptides, in complex biological matrices. These methods rely on the highly specific interaction between an antigen (analyte) and its corresponding antibody, forming a stable complex that can be measured using various detection systems. Due to their high specificity, sensitivity, and adaptability, immunoassays have become indispensable tools in clinical diagnostics, pharmaceutical development, bioanalysis, toxicology, and environmental monitoring.
One of the key advantages of immunoassay-based techniques is their ability to process large numbers of samples simultaneously, making them highly suitable for high-throughput applications. This efficiency, combined with relatively short analysis times and strong detection capabilities, has led to their widespread adoption in routine laboratory workflows. Among the different formats available, enzyme-linked immunosorbent assay (ELISA) and chemiluminescence immunoassay (CLIA) are the most commonly used in clinical and research settings. These methods offer a balance between cost-effectiveness, automation, and analytical performance.
Over time, immunoassay technologies have diversified significantly, resulting in a wide range of commercially available kits developed by different manufacturers. While this diversity has increased accessibility and flexibility, it has also introduced challenges related to measurement consistency and comparability between different assay systems.
Insulin is one of the most frequently measured proteins in clinical diagnostics. As a key peptide hormone, insulin plays a central role in regulating glucose metabolism and maintaining energy homeostasis. It facilitates glucose uptake into cells and promotes anabolic processes such as glycogen and lipid synthesis. Dysregulation of insulin production or function leads to metabolic disorders, most notably diabetes mellitus, which is characterized by chronic hyperglycemia.
Accurate measurement of insulin concentration is critical for diagnosing and managing diabetes, evaluating pancreatic β-cell function, and assessing insulin resistance. It is also important in research applications and in the development of therapeutic products, including recombinant insulin analogues. Therefore, reliable and standardized analytical methods for insulin quantification are essential.
Various analytical approaches have been developed for insulin measurement, including immunoassays, chromatographic techniques such as liquid chromatography–mass spectrometry (LC–MS), and electrochemical biosensors. While each method has its advantages, immunoassays remain the dominant choice in routine clinical laboratories due to their practicality, sensitivity, and scalability. However, significant challenges remain regarding the comparability of results obtained from different immunoassay kits and platforms.
The primary objective of this study is to evaluate the comparability of insulin measurements across different commercially available immunoassay kits. Ensuring consistency in insulin measurement is crucial because discrepancies between assays can lead to incorrect clinical interpretations, repeated testing, and inefficient use of healthcare resources. Standardization efforts, including the use of reference materials and traceability systems, have been introduced to address these issues, but variability still persists.

2. Materials and Methods
2.1 Chemicals and Reagents
This study utilized multiple commercially available immunoassay kits for insulin quantification, including four ELISA kits and three CLIA-based systems equipped with automated analyzers. These kits are commonly used in both clinical diagnostics and research laboratories.
Human serum samples were prepared from pooled donor sources to ensure homogeneity. Certified reference materials (CRMs) for human insulin were also employed to validate assay performance and assess measurement accuracy. These reference standards are critical for ensuring traceability to internationally recognized measurement systems.
All reagents, including solvents such as acetonitrile and formic acid, and proteins such as bovine serum albumin (BSA), were of analytical grade. High-purity water was used throughout the study to minimize contamination and variability.
2.2 Instrumentation
Manual ELISA assays were performed using a multimode microplate reader capable of detecting absorbance signals. For advanced analytical comparison, LC–MS was employed using a high-resolution system equipped with ultra-high-performance liquid chromatography (UHPLC). This system enabled precise detection and characterization of insulin molecules based on their mass-to-charge ratio.
2.3 Immunoassay Procedures
All immunoassay procedures were conducted according to the manufacturers’ protocols. For automated CLIA systems, the process required minimal manual intervention, as sample handling and detection were integrated into the instrument workflow.
In contrast, ELISA assays involved several manual steps, including the addition of samples and standards to microplate wells, followed by incubation with antibody reagents. Detection was achieved enzymatic reactions producing measurable optical signals.
2.4 Sample Preparation
Serum samples were thawed and equilibrated before analysis. To assess assay precision, multiple replicates were analyzed over several days, allowing evaluation of both intra-day and inter-day variability.
CRMs were diluted to cover a wide concentration range relevant to clinical measurements. Different matrices, including water, BSA solution, and human serum, were used to investigate matrix effects on assay performance.
3. Results
3.1 Variability in Serum Measurements
Significant variability was observed in insulin concentrations measured across different immunoassay kits. The reported values ranged widely, indicating inconsistencies that cannot be attributed solely to random error. Instead, systematic differences between assay systems were identified as the primary source of variation.
Even though each kit demonstrated acceptable precision individually, the lack of agreement between kits raises concerns about the reliability of insulin measurements in clinical practice. In some cases, the differences were large enough to influence clinical decision-making, potentially leading to misdiagnosis or inappropriate treatment.
An important factor contributing to this variability is the traceability of each assay to different international reference standards. Some kits were calibrated against older standards derived from modified insulin forms, while others used purified human insulin. These differences in calibration materials can significantly affect measurement outcomes.
3.2 Calibration and LC–MS Comparison
LC–MS analysis confirmed that the insulin molecules present in different calibrators were structurally identical. However, discrepancies in quantification remained due to differences in calibration approaches and assay design.
The inability to accurately quantify calibrators using LC–MS at low concentrations highlights limitations in analytical sensitivity and emphasizes the need for improved calibration strategies.
3.3 Conversion Factors and Unit Standardization
Another major source of inconsistency is the use of different conversion factors between units of measurement. Insulin concentrations are commonly reported in either μIU/mL or pmol/L, with varying conversion factors depending on the assay.
Although a standard conversion factor has been proposed, it is not universally applied. This lack of harmonization can lead to discrepancies in reported values, even when analyzing the same sample. Standardizing unit conversion practices is therefore essential for improving comparability.
3.4 Matrix Effects
Matrix effects were found to significantly influence assay performance. While simple matrices such as water and BSA showed inconsistent results, serum-based matrices produced values closer to expected concentrations.
This finding highlights the importance of using matrix-matched reference materials in assay calibration. However, currently available CRMs are typically prepared in buffer solutions, limiting their applicability in clinical contexts.
3.5 Challenges in Reference Materials
A key limitation in insulin assay standardization is the lack of commutable reference materials that behave similarly across different analytical methods. Additionally, differences in measurement principles such as molecular detection in LC–MS versus antibody binding in immunoassays further complicate standardization efforts.
4. Conclusions
This study demonstrates that significant variability exists in insulin measurements obtained using different immunoassay kits, despite acceptable precision within individual systems. These discrepancies are primarily due to differences in calibration standards, conversion factors, matrix effects, and assay design.
To improve comparability and reliability in insulin measurement, several key actions are recommended:
- Adoption of standardized reference materials with traceability to SI units
- Harmonization of conversion factors across all assay platforms
- Development of matrix-matched CRMs suitable for clinical applications
- Clear reporting of assay methods, calibration standards, and data processing procedures
Ultimately, achieving consistent and comparable insulin measurements requires a coordinated effort بين manufacturers, regulatory agencies, and the scientific community. Improved standardization will enhance diagnostic accuracy, support better patient care, and strengthen the reliability of research findings in the field of metabolic diseases.



